Serum CEA level change and its significance before and after Gefitinib therapy on patients with advanced non-small cell lung cancer
HF Qin, LL Qu, H Liu, SS Wang… - Asian Pacific Journal of …, 2013 - koreascience.kr
Objective: The aim of this study was to explore change and significance of serum carcino-
embryonic antigen (CEA) before and after gefitinib therapy in patients with advanced non …
embryonic antigen (CEA) before and after gefitinib therapy in patients with advanced non …
Association between advanced NSCLC T790 M EGFR-TKI secondary resistance and prognosis: a observational study
Y Wang, Y Wei, X Ma, X Ma, P Gong - Medicine, 2018 - journals.lww.com
Epidermal growth factor receptor (EGFR) mutations for EGFR-tyrosine kinase inhibitors
(EGFR-TKI) in non-small cell lung cancer (NSCLC) patients are with clinical benefits …
(EGFR-TKI) in non-small cell lung cancer (NSCLC) patients are with clinical benefits …
[HTML][HTML] Retrospective Evaluation of Drug-Drug Interactions With Erlotinib and Gefitinib Use in the Military Health System
TLT Luong, CN Powers, BJ Reinhardt… - Federal …, 2023 - ncbi.nlm.nih.gov
Background Erlotinib and gefitinib are epidermal growth factor receptor–tyrosine kinase
inhibitors approved for non–small cell lung cancer treatment by the US Food and Drug …
inhibitors approved for non–small cell lung cancer treatment by the US Food and Drug …
EGFR-TKI 治疗非小细胞肺癌的耐药机制进展研究
刘俊， 王长利 - 中国肿瘤临床, 2013 - cjco.cn
肺癌的发病率和死亡率已居我国恶性肿瘤的第一位. 以表皮生长因子受体,
酪氨酸激酶为靶点的酪氨酸激酶抑制剂(EGFR-TKI) 治疗肺癌已广泛引起关注 …
酪氨酸激酶为靶点的酪氨酸激酶抑制剂(EGFR-TKI) 治疗肺癌已广泛引起关注 …